University of South Florida

King Abdulaziz University

Other

Medicines for Malaria Venture

The United States Government As Represented by the Department of Veterans Affairs

Northeastern University

Oregon Health & Science University

Instituto Politecnico Nacional

Dennis Edward Kyle

Bill J Baker

Roman Manetsch

Ala Azhari

Lindsey Neil Shaw

Renee Marie Fleeman

Richard Matthew Cross

Danielle H Demers

Richard Ray Tidwell

James E Hall

Rolf W Winter

Michael Kevin Riscoe

David J Hinrichs

Jane Xu Kelly

Aaron Nilsen

Martin J Smilkstein

Max Grogl

David Lawrence Flanigan

Kwasi A Ohemeng

Alexis Nichole LaCrue

J Dieter Geratz

Brian Vesely

Jeremy Burrows

Andrii Monastyrskyi

Jordany Richarlson Maignan

Anne-Claire D Limon

James William Leahy

Raghupathi Neelarapu

John Alan Maschek

Niranjan Kumar Namelikonda

Nerida G Wilson

Christopher G Witowski

Benjamin Joe Eduful

Mario Alberto Rodriguez-Pérez

Ankush Kanwar

Linda Corrinne Barbeto

Tina Susanna Mutka

Fabian Ernesto Saenz

Cynthia L Lichorowic

Described herein are methods of epigenetic modification of fungi and uses thereof. Also described herein are compounds that can have antileishmanial activity and formulations thereof. Also described herein are methods of treating leishmanial infection in a subject that include the step of administering a compound or formulation thereof described herein to the subject.

Epigenetic modification of fungi and uses thereof

In one aspect, methods and compositions for treating parasitic diseases, for example, leishmaniasis.

Leishmania inhibitors

Novel antimicrobial compounds against drug targets such as Eskape pathogens,, and cancer are presented herein.

Antimicrobials from an epigenetics based fungal metabolite screening program

Provided herein are quinolone-based compounds that can be used for treatment and/or prevention of malaria and formulations thereof. Also provided herein are methods of treating and/or preventing malaria in a subject by administering a quinolone-based compound or formulation thereof provided herein.

Quinolone-based compounds, formulations, and uses thereof

In a screening program, the Antarctic spongewas found to produce diterpenoid secondary metabolites with activity against the leishmaniasis-causing parasite. The present invention concerns compositions useful for control ofspp. parasites in vitro and in vivo and treatment of leishmaniasis; methods for treatment of leishmaniasis; and methods for controllingspp. parasites in vitro and in vivo.

Diterpenoid membranolide compounds having anti-leishmania activity and uses thereof

The present disclosure provides compositions including a compound (e.g., compounds A-D), pharmaceutical compositions including the compound, methods of treatment of a condition (e.g., an infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.

Antimicrobial compositions, methods of use, and methods of treatment of infections

Compounds having antiparasitic or anti-infectious activity

Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones, and including, but not only, 7-(2-phenoxyethoxy)quinolin derivatives. These compounds may be administered by themselves, with at least one other derivative compound, or with other antimalarial compounds, to an animal or human subject. The therapeutic compositions can be and formulated to reduce the extent of ainfection in the recipient subject, or to reduce the likelihood of the onset or establishment of ainfection if administered prior to the parasite contacting the subject. The therapeutic compositions can be formulated to provide an effective single dose amount of an antimalarial compound or multiple doses for administering over a period of time.

4(1H)-quinolones having antimalarial activity with reduced chemical resistance

A method for treating malaria which comprises to an afflicted host patient a therapeutically effective amount of a compound have the structure of formula I: ##STR1## wherein X is O or NH; R.sub.1 is H or two R.sub.1 groups on the same amidine group together represents --(CH.sub.2).sub.m --, wherein m=2, 3 or 4; R.sub.2 is H, NH.sub.2, Cl, NO.sub.2 ; R.sub.3 is H, CH.sub.3 or CH.sub.2 CH.sub.3 and n=2-6 or a pharmaceutically acceptable salt thereof provided that when X is O, both R.sub.2 and both R.sub.3 can not be H.

Method for the treatment of malaria

This invention relates to a method for treating leishmaniasis which comprises administering to an afflicted host patient, a therapeutically effective amount of a compound having the following structure; ##STR1## wherein X is O or NH; R.sub.1 is H or two R.sub.1 of the same amidine group together represent --(CH.sub.2).sub.m -- wherein m=2, 3 or 4; R.sub.2 is H, NH.sub.2, OCH.sub.3, Cl or NO.sub.2 ; R.sub.3 is H, CH.sub.3 or CH.sub.2 CH.sub.3 and n=2-6 or a pharmaceutical acceptable salt thereof provided that X is O both R.sub.2 and both R.sub.3 cannot be H.

Method for treating leishmaniasis

Growing community of inventors

Lithia, FL, United States of America

Dennis Edward Kyle